REDWOOD CITY, Calif., July 22 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. today announced positive results from its first Phase 2 clinical study evaluating the functionality of the handheld device component of its ARX-01 Sufentanil NanoTab(TM) PCA System for management of acute post-operative pain in patients requiring opioid analgesia during hospitalization. Patients reliably self-administered sufentanil NanoTabs repeatedly over the 12-hour study without any ARX-01 System failures or dosing errors of any kind.
